29 Result(s)
within
Caroline Bodet-Milin
-
Article
Open AccessDCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach
Dynamic contrast-enhanced-MRI (DCE-MRI) is able to study bone marrow angiogenesis in patients with multiple myeloma (MM) and asymptomatic precursor diseases but its role in the management of MM has not yet bee...
-
Article
Open AccessPerformance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
The prognostic value of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) at baseline or the predictive value of minimal residual disease (MRD) detection appear as potential too...
-
Article
Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging
-
Article
Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results
Mixing diagnostic and prognostic data provided by whole-body MRI (WB-MRI) and 2-18F-fluorodeoxyglucose (2-[18F]FDG) positron emission tomography (2-[18F]FDG-PET) from a single simultaneous imaging technique for n...
-
Chapter and Conference Paper
Graph-Based Multimodal Multi-lesion DLBCL Treatment Response Prediction from PET Images
Diffuse Large B-cell Lymphoma (DLBCL) is a lymphatic cancer involving one or more lymph nodes and extranodal sites. Its diagnostic and follow-up rely on Positron Emission Tomography (PET) and Computed Tomograp...
-
Article
Whole-body MR imaging in suspected physical child abuse: comparison with skeletal survey and bone scintigraphy findings from the PEDIMA prospective multicentre study
To assess the contribution of whole-body magnetic resonance imaging (WBMRI) and bone scintigraphy (BS) in addition to skeletal survey (SS) in detecting traumatic bone lesions and soft-tissue injuries in suspec...
-
Article
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Lymphoma lesion detection and segmentation on whole-body FDG-PET/CT are a challenging task because of the diversity of involved nodes, organs or physiological uptakes. We sought to investigate the performances...
-
Article
Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials
Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is included in the International Myeloma Working Group (IMWG) imaging guidelines for the work-up at diagnosis and the follow-up ...
-
Article
Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region
To assess the rate and pattern of incidental interstitial lung abnormalities suggestive of COVID-19 on 18F-FDG PET/CT in asymptomatic cancer patients during the period of active COVID-19 circulation between Ma...
-
Chapter
New Perspectives in Imaging Techniques
The development of nuclear medicine offers new perspectives in multiple myeloma (MM) imaging. New sensitive and specific positron emission tomography (PET) imaging tracers are needed to overcome limitations of 18
-
Chapter
New Advances in Radioimmunotherapy for the Treatment of Cancers
Radioimmunotherapy (RIT) has been used for more than 30 years to diagnose and treat cancer. This approach consists of a targeted vectorization of a radionuclide by a monoclonal antibody to obtain specific irra...
-
Article
Open AccessFrom a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450
The purpose of this work was to propose an approach based on noise measurement to adapt present clinical acquisition and reconstruction parameters adapted to a PMT-based system (Biograph mCT) to a SiPM-based s...
-
Chapter and Conference Paper
Learned Deep Radiomics for Survival Analysis with Attention
In the context of multiple myeloma, patient diagnosis and treatment planning involve the medical analysis of full-body Positron Emission Tomography (PET) images. There has been a growing interest in linking qu...
-
Article
Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis
Multiple myeloma (MM) is a bone marrow cancer that accounts for 10% of all hematological malignancies. It has been reported that FDG PET imaging provides prognostic information for both baseline and therapeuti...
-
Article
Good clinical practice recommendations for the use of PET/CT in oncology
Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advan...
-
Article
18F-FDG PET/CT in multiple myeloma: critical insights and future directions
-
Chapter
Radioimmunotherapy of Lymphomas
Lymphomas are a diverse range of hematologic tumors that arise from cells of the immune system. This chapter discusses recent available clinical data on the use of radioimmunotherapy (RIT) to treat this indica...
-
Chapter
FDG PET in Multiple Myeloma
The potential of 18Fluoro-deoxyglucose (FDG) positron emission tomography (PET) for the treatment of multiple myeloma has recently been evaluated. FDG-PET is a powerful imaging tool for the detection of bone l...
-
Chapter
Prospects for Enhancing Efficacy of Radioimmunotherapy
Radioimmunotherapy has been in use for more than 20 years and has progressed significantly since its efficacy has first been demonstrated in hematology. Yet it still has limitations that prevent its large-scal...
-
Article
Open AccessPretargeting for imaging and therapy in oncological nuclear medicine
Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achi...
